|
1
|
Rubovszky G and Horváth Z: Recent advances
in the neoadjuvant treatment of breast cancer. J Breast Cancer.
20:119–131. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Gampenrieder SP, Rinnerthaler G and Greil
R: Neoadjuvant chemotherapy and targeted therapy in breast cancer:
Past, present, and future. J Oncol. 2013:7320472013. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Cain H, Macpherson IR, Beresford M, Pinder
SE, Pong J and Dixon JM: Neoadjuvant therapy in early breast
cancer: Treatment considerations and common debates in practice.
Clin Oncol (R Coll Radiol). 29:642–652. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Omarini C, Guaitoli G, Pipitone S,
Moscetti L, Cortesi L, Cascinu S and Piacentini F: Neoadjuvant
treatments in triple-negative breast cancer patients: Where we are
now and where we are going. Cancer Manag Res. 10:91–103. 2018.
View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Untch M, Konecny GE, Paepke S and von
Minckwitz G: Current and future role of neoadjuvant therapy for
breast cancer. Breast. 23:526–537. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Vila J, Teshome M, Tucker SL, Woodward WA,
Chavez-MacGregor M, Hunt KK and Mittendorf EA: Combining clinical
and pathologic staging variables has prognostic value in predicting
local-regional recurrence following neoadjuvant chemotherapy for
breast cancer. Ann Surg. 265:574–580. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Hussain SA, Palmer DH, Stevens A, Spooner
D, Poole CJ and Rea DW: Role of chemotherapy in breast cancer.
Expert Rev Anticancer Ther. 5:1095–1110. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Cuppone F, Bria E, Carlini P, Milella M,
Felici A, Sperduti I, Nisticò C, Terzoli E, Cognetti F and
Giannarelli D: Taxanes as primary chemotherapy for early breast
cancer: Meta-analysis of randomized trials. Cancer. 113:238–246.
2008. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Rastogi P, Anderson SJ, Bear HD, Geyer CE,
Kahlenberg MS, Robidoux A, Margolese RG, Hoehn JL, Vogel VG, Dakhil
SR, et al: Preoperative chemotherapy: Updates of National Surgical
Adjuvant Breast and Bowel Project Protocols B-18 and B-27. J Clin
Oncol. 26:778–785. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Margolin S, Bengtsson NO, Carlsson L,
Edlund P, Hellstrøm M, Karlsson P, Lidbrink E, Linderholm B,
Lindman H, Malmström P, et al: Scandinavian Breast Group Study SBG
2004-1: A randomised feasibility/phase II study (SBG 2004-1) with
dose-dense/tailored epirubicin, cyclophoshamide (EC) followed by
docetaxel (T) or fixed dosed dose-dense EC/T versus T, doxorubicin
and C (TAC) in node-positive breast cancer. Acta Oncol. 50:35–41.
2011. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Norton L and Simon R: The Norton-Simon
hypothesis revisited. Cancer Treat Rep. 70:163–169. 1986.PubMed/NCBI
|
|
12
|
Norton L: A Gompertzian model of human
breast cancer growth. Cancer Res. 48:7067–7071. 1988.PubMed/NCBI
|
|
13
|
Untch M, Möbus V, Kuhn W, Muck BR,
Thomssen C, Bauerfeind I, Harbeck N, Werner C, Lebeau A,
Schneeweiss A, et al: Intensive dose-dense compared with
conventionally scheduled preoperative chemotherapy for high-risk
primary breast cancer. J Clin Oncol. 27:2938–2945. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Möbus V, Jackisch C, Lück HJ, du Bois A,
Thomssen C, Kuhn W, Nitz U, Schneeweiss A, Huober J, Harbeck N, et
al; AGO Breast Study Group (AGO-B), . Ten-year results of intense
dose-dense chemotherapy show superior survival compared with a
conventional schedule in high-risk primary breast cancer: Final
results of AGO phase III iddEPC trial. Ann Oncol. 29:178–185. 2018.
View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Houssami N, Macaskill P, von Minckwitz G,
Marinovich ML and Mamounas E: Meta-analysis of the association of
breast cancer subtype and pathologic complete response to
neoadjuvant chemotherapy. Eur J Cancer. 48:3342–3354. 2012.
View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Carey LA, Dees EC, Sawyer L, Gatti L,
Moore DT, Collichio F, Ollila DW, Sartor CI, Graham ML and Perou
CM: The triple negative paradox: Primary tumor chemosensitivity of
breast cancer subtypes. Clin Cancer Res. 13:2329–2334. 2007.
View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Chen XS, Wu JY, Huang O, Chen CM, Wu J, Lu
JS, Shao ZM, Shen ZZ and Shen KW: Molecular subtype can predict the
response and outcome of Chinese locally advanced breast cancer
patients treated with preoperative therapy. Oncol Rep.
23:1213–1220. 2010.PubMed/NCBI
|
|
18
|
Balko JM, Giltnane JM, Wang K, Schwarz LJ,
Young CD, Cook RS, Owens P, Sanders ME, Kuba MG, Sánchez V, et al:
Molecular profiling of the residual disease of triple-negative
breast cancers after neoadjuvant chemotherapy identifies actionable
therapeutic targets. Cancer Discov. 4:232–245. 2014. View Article : Google Scholar : PubMed/NCBI
|
